J
Jose Goico
Researcher at University of Southern California
Publications - 9
Citations - 2199
Jose Goico is an academic researcher from University of Southern California. The author has contributed to research in topics: Gestational diabetes & Type 2 diabetes. The author has an hindex of 9, co-authored 9 publications receiving 2158 citations.
Papers
More filters
Journal ArticleDOI
Preservation of Pancreatic Beta-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
Thomas A. Buchanan,Anny H. Xiang,Ruth Peters,Siri L. Kjos,Aura Marroquin,Jose Goico,Cesar Ochoa,Sylvia Tan,Kathleen Berkowitz,Howard N. Hodis,Stanley P. Azen +10 more
TL;DR: Protection from diabetes in the troglitazone group was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization and persisted 8 months after study medications were stopped, and was associated with preservation of beta-cell compensation for insulin resistance.
Journal ArticleDOI
Effect of Pioglitazone on Pancreatic β-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational Diabetes
Anny H. Xiang,Ruth Peters,Siri L. Kjos,Aura Marroquin,Jose Goico,Cesar Ochoa,Miwa Kawakubo,Thomas A. Buchanan +7 more
TL;DR: Findings support a class effect of thiazolidinedione drugs to enhance insulin sensitivity, reduce insulin secretory demands, and preserve pancreatic beta-cell function, all in association with a relatively low rate of type 2 diabetes, in Hispanic women with prior gestational diabetes.
Journal ArticleDOI
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Thomas A. Buchanan,Anny H. Xiang,Ruth K. Peters,Siri L. Kjos,Kathleen Berkowitz,Aura Marroquin,Jose Goico,Cesar Ochoa,Stanley P. Azen +8 more
TL;DR: The predominant response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes was a reduction in insulin release to maintain nearly constant glucose tolerance.
Journal ArticleDOI
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Kathleen Berkowitz,Ruth Peters,Siri L. Kjos,Jose Goico,Aura Marroquin,Meleana E. Dunn,Anny H. Xiang,Stanley P. Azen,Thomas A. Buchanan +8 more
TL;DR: Troglitazone improved whole-body insulin sensitivity and lowered circulating insulin concentrations in women with prior GDM who are at very high risk for NIDDM, and the greatest improvement occurred in the women who had the highest diastolic blood pressures and the best IVGTT insulin responses during baseline testing.
Journal ArticleDOI
Changes in Insulin Sensitivity in Response to Troglitazone Do Not Differ Between Subjects With and Without the Common, Functional Pro12Ala Peroxisome Proliferator–Activated Receptor-γ2 Gene Variant Results from the Troglitazone in Prevention of Diabetes (TRIPOD) study
Soren Snitker,Richard M. Watanabe,Ifeanyi Ani,Anny H. Xiang,Aura Marroquin,Cesar Ochoa,Jose Goico,Alan R. Shuldiner,Thomas A. Buchanan +8 more
TL;DR: Among young Hispanic women at high risk for type 2 diabetes, the Pro12Ala variant of the PPAR-gamma receptor gene did not explain the failure of approximately 1/3 of subjects to increase their insulin sensitivity when placed on troglitazone at a dose of 400 mg/day.